230 results
Page 2 of 12
8-K/A
EX-99.2
27eqciroej pcpsug
29 Sep 23
Completion of Acquisition or Disposition of Assets
4:01pm
8-K/A
EX-99.3
n37sz9e97g4al
29 Sep 23
Completion of Acquisition or Disposition of Assets
4:01pm
8-K/A
EX-99.1
ug6pi40 f0xtmukr
29 Sep 23
Completion of Acquisition or Disposition of Assets
4:01pm
8-K
EX-99.1
04nn7 b30dioepp
17 Aug 23
Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma
4:15pm
8-K
EX-4.3
txgia21qbrxb4xjbzc2r
17 Aug 23
Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma
4:15pm
8-K
EX-4.1
x274 vuns
17 Aug 23
Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma
4:15pm
8-K
EX-4.2
rfgf25hpxhba2uibia
17 Aug 23
Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma
4:15pm
8-K
35aheyuv1wrdc6o5n
17 Aug 23
Diffusion Pharmaceuticals Stockholders Approve Merger with EIP Pharma
4:15pm
425
EX-99.1
vbh8e7e
14 Aug 23
Business combination disclosure
4:16pm
425
beoz tz9b7yuk66aua
14 Aug 23
Business combination disclosure
4:16pm
8-K
39485e 8ezuxmjzh
14 Aug 23
EIP Pharma Announces First Patient Dosed in RewinD-LB Phase 2b Clinical Trial Evaluating Neflamapimod in Dementia with Lewy Bodies
4:15pm
8-K
EX-99.1
dynn vowi3k
14 Aug 23
EIP Pharma Announces First Patient Dosed in RewinD-LB Phase 2b Clinical Trial Evaluating Neflamapimod in Dementia with Lewy Bodies
4:15pm
425
fyza jkd2d4hssl
9 Aug 23
Business combination disclosure
4:02pm
425
EX-99.1
cj91ctm
9 Aug 23
Business combination disclosure
4:02pm
425
EX-99.2
hiowsv
9 Aug 23
Business combination disclosure
4:02pm
8-K
EX-99.2
c7bmy32d0iv044
9 Aug 23
Other Events
4:02pm
8-K
EX-99.1
668mliipifbr931xjm5
9 Aug 23
Other Events
4:02pm
8-K
r446wl
9 Aug 23
Other Events
4:02pm